Skip to main content
. 2020 Sep 29;40(9):BSR20201361. doi: 10.1042/BSR20201361

Figure 2. MiR-26a was involved in the migration of HaCaT cells.

Figure 2

(A,B) The level of miR-26a after transfection of anti-miR-26a or miR-26a was detected by qRT-PCR. (C,D) The migration ability of TGF-β1-treated HaCaT cells after transfection of anti-miR-26a was measured by wound healing assay. (B) The migration ability of TGF-β1-treated HaCaT cells after transfection of miR-26a was examined by wound healing assay. Con, no treatment. TGF-β1, treatment with 2 ng/ml TGF-β1 for 24 h. TGF-β1+anti-miR-NC, treatment with 2 ng/ml TGF-β1 and transfection with miR-26a inhibitor negative control. TGF-β1+anti-miR-26a, treatment with 2 ng/ml TGF-β1 and transfection with miR-26a inhibitor. TGF-β1+miR-NC, treatment with 2 ng/ml TGF-β1 and transfection with miR-26a negative control. TGF-β1+miR-26a, treatment with 2ng/ml TGF-β1 and transfection with miR-26a inhibitor. * means P-vvalue less than 0.05.